This study evaluated the most effective and safe dose of dapagliflozin (Farxiga) as an additional treatment to insulin in patients with type 1 diabetes (T1D). The authors concluded that 10 mg of dapagliflozin as an add-on to insulin treatment resulted in improved blood glucose (sugar) control, reduced insulin dosage, and body weight without causing an elevated risk of low blood glucose in these patients.

This study evaluated the effects of the plant-based polyphenol-rich extract TOTUM-63 on glucose control in patients with prediabetes or early-stage newly diagnosed type 2 diabetes (T2D). The data showed that TOTUM-63 was safe and lowered fasting blood glucose in these patients. 

This study evaluated the effectiveness and safety of combinations of anti-depressive medication for the treatment of diabetic peripheral neuropathic pain (DPNP) in patients with diabetes. The study showed that combination treatment improved pain in these patients and was well tolerated. 

This analysis investigated the relationship between anti-diabetic medications and the risk of fractures in patients with type 2 diabetes (T2D). The data showed that glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sulfonylurea (SU) provided better protection against fractures compared to thiazolidinedione (TZD) or dipeptidyl peptidase-4 inhibitors (DPP-4is) while sodium-glucose cotransporter-2 inhibitors (SGLT-2i) increased the risk of fractures compared to GLP1-RAs.

This study analyzed the long-term effect of behavioral counseling on increasing daily physical activity (PA) and reducing sedentary (SED) time on changes in beta-cell (β-cell) function and glucose control in patients with type 2 diabetes (T2D). The authors concluded that increasing moderate-to-vigorous-intensity physical activity (MVPA) and reducing SED time can effectively preserve the β-cell function of the pancreas and improve glucose control in these patients.

This study examined the effects of consuming soymilk and probiotics on risk factors related to heart and blood vessel diseases in patients with type 2 diabetes (T2D). The study showed that the consumption of soymilk with probiotics might improve cardiovascular (CV) risk factors in these patients.

This review assessed the effectiveness and safety of ultra-rapid insulin analogs (URIAs) with continuous subcutaneous insulin systems (CSII) in adults with type 1 diabetes (T1D). The authors concluded that URIAs were compatible with CSII systems and had a better glucose-lowering effect after meals compared to rapid-acting insulin analogs (RAIAs) but may need more infusion set changes.

This study compared the safety and effectiveness of different doses of an oral insulin capsule formulation (Capsulin™) to patients with early-stage type 2 diabetes (T2D). The data showed that twice-daily, orally administered Capsulin at a dose of 150 international units (IU) was safe and resulted in a significant lowering of glycated hemoglobin (HbA1c; blood glucose control over the past 2-3 months), fasting plasma glucose (FPG) and triglycerides (TG; blood fats) levels.

This review assessed the effect of vitamin B12 supplementation on clinical outcomes when used alone or combined with other treatments for diabetic peripheral neuropathy (PN). The authors concluded that a greater reduction of PN symptoms occurred with the use of B12 supplementation alone or in combination with other treatments compared to placebo.

This study compared the occurrence of infections and identified their risk factors in patients with rheumatoid arthritis (RA) that were treated with tofacitinib (Xeljanz) against those given a tumor necrosis factor inhibitor (TNFi). The data showed that serious and non-serious infections were higher in patients that received tofacitinib compared to a TNFi.